BEAM vs EXAS · rev $63.5M vs rev $2.76B
Beam Therapeutics Inc (BEAM) versus EXACT Sciences Corporation (EXAS) — a side-by-side from cached financials, not a winner call.
Beam Therapeutics Inc (BEAM) is a biotechnology company listed on US.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Latest reported BEAM revenue for 2024-12-31 was $63.5M. Net income was -$376.7M. Revenue was down 83.2% from 2023-12-31 to 2024-12-31. BEAM currently screens at market cap $2.01B.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
BEAM currently screens at market cap $2.01B. EXAS currently screens at market cap $20.03B.
Not investment advice. Open the BEAM and EXAS stock pages for the full models.
Not investment advice.